

Antimicrobial Resistant Infections was published in the **Federal Register** on July 8, 1997, (62 FR 36541). The notice is amended as follows:

On page 36543, under the heading "Specific Instructions," second column, 4. Objectives and Technical Approach, lines three and four have been changed and should read: "Recipient Activities (A.1.a., A.1.b., A.2., A.3., and A.4.). . . ."

On page 36544, second column, third paragraph, c., line six should read "Activities A.4.). . . ."

All other information and requirements of the July 8, 1997, **Federal Register** notice remain the same.

Dated: July 25, 1997.

Joseph R. Carter,

Acting Associate Director for Management and Operations, Centers for Disease Control and Prevention (CDC).

[FR Doc. 97-20136 Filed 7-30-97; 8:45 am]

BILLING CODE 4163-18-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

Request for Nominations for Members on Public Advisory Committees; Blood Products Advisory Committee

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is requesting nominations to fill upcoming vacancies on the Blood Products Advisory Committee.

FDA has a special interest in ensuring that women, minority groups, and individuals with disabilities are adequately represented on advisory committees and, therefore, extends particular encouragement to nominations for appropriately qualified female, minority, or disabled candidates.

DATES: Nominations should be received on or before August 15, 1997.

ADDRESSES: All nominations for membership should be sent to the appropriate contact person (address below).

FOR FURTHER INFORMATION CONTACT:

All nominations and curricula vitae except for consumer representatives should be submitted in writing to Linda A. Smallwood, Office of Blood Research and Review (HFM-350), Center for Biologics Evaluation and Research, Food and Drug Administration, 1401 Rockville Pike, Rockville, MD

20852-1448, 301-827-3514.

All nominations and curricula vitae for consumer representatives should be submitted in writing to Annette J. Funn, Office of Consumer Affairs (HFE-88), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-827-5006.

SUPPLEMENTARY INFORMATION: FDA is requesting nominations to fill upcoming vacancies on the Blood Products Advisory Committee. The function of the committee is to review and evaluate available data concerning the safety, effectiveness, appropriate use of blood products derived from blood and serum or biotechnology which are intended for use in the diagnosis, prevention, or treatment of human diseases, and, as required, any other product for which FDA has regulatory responsibility. Persons nominated for membership should be among authorities knowledgeable in the fields of clinical and administrative medicine, infectious disease, hematology, immunology, transfusion medicine, surgery, internal medicine, biochemistry, biostatistics, epidemiology, biological and physical sciences, biotechnology, computer technology, sociology/ethics, and other related professions. The membership will also include representatives of consumer organizations, product recipients, and health care providers. The committee will function at times as a medical device panel under the Federal Food, Drug, and Cosmetic Act Medical Device Amendments of 1976.

Nonvoting Consumer and Industry Representation

Section 520(f)(3) of the Federal Food, Drug, and Cosmetic Act (the act) (21 U.S.C. 360j(f)(3)), as amended by the Medical Device Amendments of 1976, provides that each medical device panel include as members one nonvoting representative of consumer interests and one nonvoting representative of interests of the manufacturing industry.

Nomination Procedures

Interested persons may nominate one or more qualified persons for membership on the committee. Self nominations are also accepted. A current curriculum vitae of each nominee should accompany the letter of nomination and include the following information: Full name and title, business address and phone number, home address and phone number, date and place of birth. Nominations shall state that the nominee is willing to serve as a member of the committee and appears to have no conflict of interest that would preclude advisory committee membership. The Commissioner of

Food and Drugs will ask the potential candidates to provide detailed information concerning such matters as financial holdings, consultancies, and research grants or contracts to permit evaluation of possible sources of conflict of interest. The term of office may not exceed 4 years, depending on the appointment date.

The nomination procedures for the nonvoting consumer representative and industry representative are the same as stated previously with the following exceptions:

Consumer Representatives

To be eligible for selection, the applicant's experience and/or education will be evaluated against Federal civil service criteria for the position to which the person will be appointed. The term of office is up to 4 years.

Industry Representatives

Any organization representing industry interests wishing to participate in the selection of representatives may nominate one or more qualified persons to represent industry interests. Persons who nominate themselves as industry representatives will not participate in the selection process. It is, therefore, recommended that all nominations be made by someone with an organization, trade association, or firm who is willing to participate in the selection process. Nominees shall be full-time employees of firms that manufacture products that would come before the committee, or consulting firms that represent manufacturers. The term of office is up to 4 years.

Selection Procedures

Consumer Representatives

Selection of members representing consumers interests is conducted through procedures which include use of a consortium of consumer organizations which has the responsibility for recommending candidates for the agency's selection. Candidates should possess appropriate qualifications to understand and contribute to the committee's work.

Industry Representatives

Regarding nominations for members representing the interests of industry, a letter will be sent to each person that has made a nomination, and to those organizations indicating an interest in participating in the selection process, together with a complete list of all such organizations and the nominees. This letter will state that it is the responsibility of each nominator or

organization indicating an interest in participating in the selection process to consult with the others in selecting a single member representing industry interests for the committee within 60 days after receipt of the letter. If no individual is selected within 60 days, the agency will select the nonvoting member representing industry interests.

This notice is issued under the Federal Advisory Committee Act (5 U.S.C. app. 2), relating to advisory committees.

Dated: July 24, 1997.

Michael A. Friedman,

Deputy Commissioner for Operations.

[FR Doc. 97-20080 Filed 7-30-97; 8:45 am]

BILLING CODE 4160-01-F

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

Request for Nominations for Members on Public Advisory Committees; Science Board to the Food and Drug Administration

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is requesting nominations for members to serve on the Science Board to the Food and Drug Administration (the board) administered from FDA's Office of Science. Nominations will be accepted for upcoming vacancies that may or will occur on the board during the next 24 months.

FDA has a special interest in ensuring that women, minority groups, and individuals with disabilities are adequately represented on advisory committees, and therefore, extends particular encouragement to nominations for appropriately qualified female, minority, or physically disabled candidates. Final selections from among qualified candidates for each vacancy will be determined by the expertise required to meet specific agency needs and in a manner to ensure appropriate balance of membership.

DATES: All nominations must be received by September 2, 1997.

ADDRESSES: All nominations for membership and curricula vitae from academia, industry, and government, except for general public representatives (consumer-nominated members), should be sent to Susan K. Meadows (address below). All nominations for general public representatives (consumer-nominated members) should be sent to Annette J. Funn (address below).

FOR FURTHER INFORMATION CONTACT:

Regarding all nominations for membership, except for general public representatives: Susan K. Meadows, Office of Science (HF-32), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-827-4591.

Regarding all nominations for general public representatives: Annette J. Funn, Office of Consumer Affairs (HFE-88), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-827-5006.

SUPPLEMENTARY INFORMATION: FDA is requesting nominations for members to serve on the board for upcoming vacancies that may or will occur on the board during the next 24 months.

Function

The function of the board is to provide advice primarily to the agency's Senior Science Advisor and, as needed, to the Commissioner of Food and Drugs and other appropriate officials on specific complex and technical issues as well as emerging issues within the scientific community in academia and industry. Additionally, the board provides advice to the agency on keeping pace with technical and scientific evolutions in the field of regulatory science, on formulating an appropriate research agenda and on upgrading its scientific and research facilities to keep pace with these changes. The board also provides the means for critical review of agency-sponsored intramural and extramural scientific research programs.

Criteria for Members

Persons nominated for membership shall have exceptional accomplishments and expertise in science, or executive level experience in scientific programmatic or laboratory management involving scientific endeavors appropriate to the work of the board and the interests of FDA. Disciplines or expertise of particular interest include biomedical technology with application to medical devices, biologics and vaccine development and research, and genetics. The term of office is 4 years.

General Public Representatives (Consumer-nominated Members)

FDA currently attempts to place members on advisory committees who are nominated by consumer organizations. These members are recommended by a consortium of 12 consumer organizations that has the responsibility for screening, interviewing, and recommending consumer-nominated candidates with appropriate scientific credentials.

Candidates are sought who are aware of the consumer impact of committee issues, but who also possess enough technical background to understand and contribute to the committee's work. The agency notes, however, that for some advisory committees, it may require such nominees to meet the same technical qualifications and specialized training required of other expert members of the committee. The term of office for these members is up to 4 years, depending on the appointment date. Nominations are invited for consideration for membership as openings become available.

Nomination Procedures

Any interested person may nominate one or more qualified persons for membership on the board. Nominations shall state that the nominee is aware of the nomination, is willing to serve as a member of the board, and appears to have no conflict of interest that would preclude board membership. Potential candidates will be asked by FDA to provide detailed information concerning such matters as financial holdings, consultancies, and research grants or contracts in order to permit evaluation of possible sources of conflict of interest.

This notice is issued under the Federal Advisory Committee Act (5 U.S.C. app. 2) and 21 CFR part 14, relating to advisory committees.

Dated: July 24, 1997.

Michael A. Friedman,

Deputy Commissioner for Operations.

[FR Doc. 97-20082 Filed 7-30-97; 8:45 am]

BILLING CODE 4160-01-F

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. 97F-0305]

Goldschmidt Chemical Corp.; Filing of Food Additive Petition

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that Goldschmidt Chemical Corp. has filed a petition proposing that the food additive regulations be amended to provide for the expanded safe use of siloxanes and silicones; cetylmethyl, dimethyl, methyl 11-methoxy-11-oxoundecyl as a pigment dispersant in all pigmented polymers intended for use in contact with food.